Alnylam Pharmaceuticals Inc (ALNY)vsCorMedix Inc (CRMD)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
CRMD
CorMedix Inc
$8.36
-2.11%
HEALTHCARE · Cap: $669.98M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 972% more annual revenue ($4.29B vs $400.05M). CRMD leads profitability with a 45.3% profit margin vs 12.6%. CRMD trades at a lower P/E of 3.9x. CRMD earns a higher WallStSmart Score of 80/100 (B+).
ALNY
Strong Buy65
out of 100
Grade: B-
CRMD
Strong Buy80
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for CRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 41 in profit
Keeps 45 of every $100 in revenue as profit
Strong operational efficiency at 50.0%
Revenue surging 226.1% year-over-year
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 45.3% and operating margin at 50.0%. Revenue growth of 226.1% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : CRMD
The primary concerns for CRMD are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
CRMD carries more volatility with a beta of 1.47 — expect wider price swings.
CRMD is growing revenue faster at 226.1% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CRMD scores higher overall (80/100 vs 65/100), backed by strong 45.3% margins and 226.1% revenue growth. ALNY offers better value entry with a 86.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?